ACC 2026: Post-TAVR treatments show potential in reducing cardiovascular risks
At ACC 2026, retrospective results were presented demonstrating the possibility of using pharmacotherapies for patients after the completion of a TAVR procedure.
Comment & Opinion
Companion diagnostics: the cornerstone of precision medicine
Epic secures a £222m federated EPR contract across Somerset and Dorset
Knight Therapeutics advances chronic GvHD expansion strategy
Gender bias in AI health advice: when innovation learns from incomplete data
JPM26: Ypsomed commits to self-care delivery devices in new strategic plan
JPM26: Opus Genetics builds momentum in rare retinal gene therapy
JPM26: Butterfly Network aims to close the global medical imaging gap
